A19: Rituximab Therapy has a Rapid and Durable Response for Refractory Cytopenia in Childhood-Onset Systemic Lupus Erythematosus.

MLA

Olfat, Mohammed, et al. “A19: Rituximab Therapy Has a Rapid and Durable Response for Refractory Cytopenia in Childhood-Onset Systemic Lupus Erythematosus.” Arthritis & Rheumatology, vol. 66, Mar. 2014, p. S30. EBSCOhost, https://doi.org/10.1002/art.38435.

APA

Olfat, M., Silverman, E. D., & Levy, D. M. (2014). A19: Rituximab Therapy has a Rapid and Durable Response for Refractory Cytopenia in Childhood-Onset Systemic Lupus Erythematosus. Arthritis & Rheumatology, 66, S30. https://doi.org/10.1002/art.38435

Chicago

Olfat, Mohammed, Earl D. Silverman, and Deborah M. Levy. 2014. “A19: Rituximab Therapy Has a Rapid and Durable Response for Refractory Cytopenia in Childhood-Onset Systemic Lupus Erythematosus.” Arthritis & Rheumatology 66 (March): S30. doi:10.1002/art.38435.